Government shutdown doesn’t stop Gossamer floating by Phil Taylor Thursday, January 24, 2019 Gossamer Bio isn’t letting the government shutdown put a brake on its financing plans as it files for a $230 million IPO.
Things could get hairy at FDA if shutdown continues: analysts by Phil Taylor Wednesday, January 23, 2019 The FDA is still holding it together during the government shutdown but could face big problems if it extends for another month and user fees dry up.
Immunochina raises $20M for blood cancer CAR-T by Phil Taylor Tuesday, January 22, 2019 Fresh from reporting clinical data at ASH, Immunochina has raised $20 million to speed up its CAR-T development programs.
Redx cleared to start Wnt cancer trial again after safety scare by Phil Taylor Monday, January 21, 2019 Redx was hit hard last year when it was forced to suspend a phase 1/2a trial of its porcupine inhibitor for solid tumors, but it’s now been given the OK to restart testing.
Former Insmed CMO Streck resurfaces at Alder by Phil Taylor Friday, January 18, 2019 A few days after leaving Insmed to take up an “employment opportunity on the West Coast”, Paul Streck has popped up at migraine specialist Alder.
It's a case of déjà vu as Alzheon pulls IPO again by Phil Taylor Thursday, January 17, 2019 Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.
Five Prime cuts 41 jobs, narrows focus to clinical-stage drugs by Phil Taylor Wednesday, January 16, 2019 Immuno-oncology player Five Prime is axing 20% of its workforce and its early-stage R&D in order to focus on its clinical cancer programs.
Aimmune says shutdown blocks peanut allergy drug review by Phil Taylor Tuesday, January 15, 2019 Aimmune has confirmed that the government shutdown will delay the FDA’s review of AR101, its oral immunotherapy for peanut allergy.
Aslan fails to roar as lead drug flunks phase 2 trial by Phil Taylor Monday, January 14, 2019 Aslan has been hit by the news that its lead drug varlitinib missed the mark in a gastric cancer trial, sending its shares down almost 16%.
hVIVO preps phase 3 for ‘universal’ flu vaccine by Phil Taylor Friday, January 11, 2019 U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
